Table 1.
Clinical and demographic data as well as brain volumetric measurements of relapsing-remitting multiple sclerosis (RRMS) patients and healthy controls (HC) at the baseline MR scan.
| Clinical data | MS (n = 12) | HC (n = 12) | p-value |
|---|---|---|---|
| Gender (female/male) | 7/5 | 4/8 | 0.414(a) |
| Mean age at baseline MRI (SD) [years] | 41.7 (11.5) | 33.5 (9.6) | 0.078(b) |
| Mean age at disease onset (SD) [years] | 38.3 (12.8) | — | — |
| Mean disease duration (SD) [months] | 35.8 (71.3) | — | — |
| Median EDSS (range) | 1.5 (0–2.5)(c) | — | — |
| Mean FSMC (SD) | 43 (21.2)(c) | — | — |
| DMD (no/first-line/second-line) | 4/6/2 | — | — |
| Volumetric analysis | |||
| Mean WM fraction (SD) [%] | 41.4 (2.8) | 39.0 (3.9) | 0.356(b) |
| Mean GM fraction (SD) [%] | 42.0 (3.2) | 45.4 (3.7) | 0.021(b) |
| Mean BP fraction (SD) [%] | 83.3 (2.3) | 84.4 (2.2) | 0.166(b) |
| Mean T2 WM lesion volume (SD) [ml] | 4.6 (5.4) | — | — |
(a)p-value derived from Pearson’s chi-square test.
(b)p-values derived from Mann-Whitney test.
(c)no significant difference in EDSS and FSMC over time between baseline (t1 = 0 months) and the last follow-up (t5 = 12 months) using Wilcoxon signed-rank test (both p-values p > 0.05).
(d)first-line: glatiramer acetate or interferon-beta; second-line: natalizumab.
SD Standard deviation.
EDSS Expanded Disability Status Scale.
FSMC Fatigue Scale for Motor and Cognitive functions.
WM White matter.
GM Grey matter.
BP Brain parenchymal.
DMD Disease-modifying drugs.